Together, our results indicate that melanoma cells upregulate T-RECS in response to MEK-targeting therapy, and that T-RECS is a druggable vulnerability to either augment the anti-tumor response to MEK inhibition, or to restore therapeutic response in melanoma cells that have become resistant to MEK inhibition. Here, MAP2K7 is linked to neoplasm.